JMCC Group announced its second international distribution deal this month. The new agreement will see London-based LYPHE Group Limited, which supports more than 60% of the British patient market, distributing JMCC’s high-quality, GMP-certified medical cannabis throughout the UK. JMCC’s sustainable, greenhouse-grown products will be shipped from JMCC’s cultivation and processing facilities in Jamaica to its new, state-of-the-art distribution centre on the Channel Island of Jersey and on to LYPHE Group’s dispensing arm, Dispensary Green, for distribution to its UK patients. LYPHE Group will also distribute JMCC products to patients through its clinic in Jersey.
Both JMCC and LYPHE are partners in Project Twenty21, a patient registry sponsored by Drug Science, the leading independent scientific body on drugs in the UK. Project Twenty21 is creating the UK’s largest body of evidence for the effectiveness and tolerability of medical cannabis, to secure NHS funding of prescriptions for patients for whom the benefits of treatment with medicinal cannabis are proven to outweigh the potential risks.
JMCC will begin supplying EU GMP-certified medicinal cannabis to patients registered in Project Twenty21 in Q2 2021, as the only Canadian company and exclusive supplier from the Caribbean region. LYPHE Group’s The Medical Cannabis Clinics (TMCC), the UK trailblazer in cannabis telehealth, operates a national network of highly qualified doctors with leading expertise in consulting and prescribing for medical cannabis patients. TMCC is supporting Project Twenty21 patients via its virtual clinic platform.
“At the core of JMCC’s philosophy is ensuring the highest possible quality and a reliable, seamless experience for patients. We’re delighted that our newest partner is one that is so well positioned to help ensure that patients across the UK will receive that seamless, consistent experience with JMCC medical cannabis products,” said JMCC Group Chair & CEO Diane Scott. “LYPHE has already earned the trust of thousands of patients for the very high level of knowledge and advice about cannabis-based medical products its prescribers provide as well as ongoing care and support.”
“We believe we’re putting JMCC’s products – and the patients who will be using them — into very good hands.”
“While patients in the UK are continuing to struggle with both access to and affordability of medical cannabis, they’re also becoming increasingly knowledgeable and demanding about safety, quality and consistency,” said Jonathan Nadler, LYPHE Group Managing Director.
“Many are also looking for products that are as naturally grown and sustainably produced as possible. So, on all of these counts, we’re very pleased to be adding JMCC products to our formulary.”
Headquartered in Toronto, Canada, JMCC Group is a fully integrated medical cannabis company, operating within a self-contained supply chain – from propagation and cultivation of raw material supply, product development, manufacturing and packaging, and through to global logistics and distribution. Founded in 2016, today, JMCC is the leading global provider of premium Jamaican medical cannabis products and services to the world.
JMCC European Distribution Limited (JEDL) is a joint-venture, state-of-the-art distribution centre between JMCC (Canada) Corp as majority owner and Jersey’s Green Island Growers Ltd. JEDL augments JMCC Group’s global Distribution division in Jamaica, where the company also cultivates and processes its high-quality medical-grade cannabis. The Distribution division offers world-class logistics and warehousing services to third-party customers such as licensed producers, distributors and medical cannabis product manufacturers.
Learn more at www.jamaicanmedicann.com.
As Europe’s medical cannabis health tech leader, LYPHE operates the region’s most popular cannabis clinical telehealth and dispensing ecosystem. LYPHE’s The Medical Cannabis Clinics (TMCC) are the UK frontrunners in cannabis telehealth, operating a national network of highly qualified doctors with leading expertise in consulting and prescribing for medical cannabis patients. TMCC has conducted more than 5,000 patient consultations to date. Learn more at: https://lyphegroup.com/